Skip to content
Fear and GreedStocks25Crypto22
Start for free

Enovis stock

ENOVNYSE

Enovis Corporation, HealthcareISIN US1940145022

$27.64▼ $0.91 (−3.2%)Closing price of 12 Nov 2026

45Score 45 out of 100, Weak

Turn on early warning

Price and trend

74 / 100

Price history

−12% in one year

The chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Above the 200-day line: the price is 19% above it.

Trend change

Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.

Momentum

Normal: the price is neither overheated nor sold off (RSI 68).

Distance to the high

The price is 12% below its 52-week high. Largest decline in 19 years: 86% (July 2014 to October 2026).

Chart figures for advanced users
SMA 50$20.36
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$23.21
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)68
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$17.43
The lowest closing price of the last twelve months.
Resistance$31.42
The highest closing price of the last twelve months.
What would $1,000 in Enovis have become?Return triangle for Enovis
Market cap
$1.59B
Div. yield
no dividend
Loss
includes one-off items, adjusted 7.6
7.9
on earnings for the next twelve months ($3.49 per share)
Fair value
no data

Snapshot

Computed from the data by fixed rules, no AI

  • Enovis Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $1.59B, is number 46 of 88 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $2.25B (up 6.7% year on year) and a loss of $1.18B.
  • For fiscal 2026, analysts expect on average revenue of $2.34B (up 3.9%) and adjusted earnings per share of $3.70 (up 12.1%).
Show more
  • MEQIRI Score 45 out of 100 (Weak): rank 452 of 702 in Healthcare, median 53.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

None of our strength checks applies.

Weaknesses

  • DilutionShare count up 25% since 2020.Capital allocation 23
  • Loss-makingLoss of $527.4M over the last 12 months.Fundamentals 38
  • Volatile share priceVolatility 68% a year over the last 12 months.Stability 44
45/ 100
MEQIRI Score
Weak

Its standout strength is technical analysis, while profitability and capital allocation hold the score back.

Daily figure as of 13 Nov 2026

How the score is calculated

Score overview

Fundamental quality fluctuates.

Profit consistency50% of years
Cash conversion (free cash flow to earnings, 12 months)not measured
ROIC (12 months)2.4%
Positive free cash flow80% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Valuation

Valuation signal

not measured
Price
$27.64
Fair value
not meaningful
Gap to fair value
no data

A fair value is not meaningful here, so the signal follows the valuation grade.

Valuation metrics

no data
no data
Fair value (model)
no data

The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

20 years

In the twelve months to 2 Oct 2026, revenue rose 3.3% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.

Margins

20 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 60%, operating −1%, net −53%. Last 12 months: net −23%.

Debt & balance sheet

latest quarter
0.9
−32.3x
2.15
Cash & equivalents
$65.35M

Debt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.

Earnings

Next earnings
25 Feb 2027in 104 days
Last reported
5 Nov 2026EPS reported $0.88 (expected $0.77)above expectations

Analyst estimates

Earnings estimates have barely changed since 15 Oct 2026.

Fiscal 20269 analysts
Earnings per share
$3.70+2.0%
Revenue
$2.34B−0.1%
Fiscal 20279 analysts
Earnings per share
$3.46−2.3%
Revenue
$2.45B−0.2%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook confirmed

Share price after the results: +6.7%

2026 guidance reaffirmed, revenue split evenly between the two halves, free cash flow conversion above 25%.

Supporting passage from the call, verbatim
“We continue to expect free cash flow conversion of greater than 25% in 2026 as we've laid out in our prior calls. We are reaffirming our 2026 guidance.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

4 insiders bought on the open market in the last 6 months, $691,629 in total.

  • Wienbar Sharon LPurchase

    11 Nov 2026, Board

    Shares
    900
    Price
    $27.76
    Value
    $24,984
  • Lalor Angela SPurchase

    11 Nov 2026, Board

    Shares
    870
    Price
    $28.86
    Value
    $25,108
  • Wienbar Sharon LPurchase

    10 Nov 2026, Board

    Shares
    874
    Price
    $28.43
    Value
    $24,848
Show 11 more
  • Lalor Angela SPurchase

    10 Nov 2026, Board

    Shares
    887
    Price
    $28.28
    Value
    $25,084
  • Wienbar Sharon LPurchase

    9 Nov 2026, Board

    Shares
    924
    Price
    $26.98
    Value
    $24,930
  • Wienbar Sharon LPurchase

    6 Nov 2026, Board

    Shares
    907
    Price
    $27.55
    Value
    $24,988
  • Engert OliverPurchase

    4 Sept 2026, Chief Administrative Officer

    Shares
    2,660
    Price
    $18.80
    Value
    $50,008
  • McDonald DamienPurchase

    4 Sept 2026, Chief Executive Officer

    Shares
    13,035
    Price
    $19.15
    Value
    $249,620
  • Engert OliverPurchase

    3 Sept 2026, Chief Administrative Officer

    Shares
    5,140
    Price
    $19.46
    Value
    $100,024
  • Engert OliverPurchase

    2 Sept 2026, Chief Administrative Officer

    Shares
    2,458
    Price
    $20.32
    Value
    $49,947
  • Engert OliverPurchase

    15 Jun 2026, Chief Administrative Officer

    Shares
    1,000
    Price
    $20.92
    Value
    $20,920
  • Engert OliverPurchase

    11 Jun 2026, Chief Administrative Officer

    Shares
    1,200
    Price
    $21.62
    Value
    $25,948
  • Engert OliverPurchase

    10 Jun 2026, Chief Administrative Officer

    Shares
    1,000
    Price
    $23.00
    Value
    $23,000
  • Engert OliverPurchase

    1 Jun 2026, Chief Administrative Officer

    Shares
    1,000
    Price
    $22.22
    Value
    $22,220

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Enovis

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

702 rated companies in Healthcare

Rank 452 of 702
452/ 702
This company
45
Sector median
53

Categories against the sector medianMedian of 702 companies

Profitability29 (median 38)9 below the median
Growth52 (median 54)2 below the median
Fundamentals38 (median 46)8 below the median
Stability44 (median 67)23 below the median
Capital allocation23 (median 39)16 below the median
Technical analysis74 (median 69)5 above the median
Momentum59 (median 70)11 below the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Devices)

The next larger and next smaller companies by market value

All 88 Medical (Devices) stocks

ETFs that hold Enovis

Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
Avantis Global Small Cap Value UCITS ETFAVWS0.16%0.39%€1.49B
iShares S&P SmallCap 600 UCITS ETFIUS30.09%0.30%€2.31B
L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ0.06%0.30%€185.82M
Show 5 more
State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR0.06%0.30%€4.28B
Xtrackers Russell 2000 UCITS ETF 1CXRS20.06%0.30%€2.22B
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG0.05%0.43%€2.5B
State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV0.04%0.30%€964.08M
iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG0.03%0.10%€395.74M

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2024)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy